Cellectar Biosciences, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Cellectar Biosciences, Inc. (CLRB) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $257.97 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2014-03-19.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2014-03-19
- Cellectar Biosciences, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2011 was $257.97K, a 20.67% increase from fiscal 2010.
- Cellectar Biosciences, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2010 was $213.79K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2011-12-31 | $257.97K 10-K · filed 2014-03-19 |
| 2010-12-31 | $213.79K 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |